Online Figure 1





Online Figure 2







Appendix 1

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	5-8
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	5-8
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	10
Objectives	3	State specific objectives, including any prespecified hypotheses	11
Methods			
Study design	4	Present key elements of study design early in the paper	11
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	11
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants	12
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	12-15
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	13, 15
Bias	9	Describe any efforts to address potential sources of bias	11, 12
Study size	10	Explain how the study size was arrived at	15
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	14, 15
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	15
		(*b*) Describe any methods used to examine subgroups and interactions	15
		(*c*) Explain how missing data were addressed	15, 16

Eur Radiol (2020) Feger S, Ibes P, Napp A et al

		(*d*) If applicable, describe analytical methods taking account of sampling strategy	8
		(*e*) Describe any sensitivity analyses	n.a.
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	16
		(b) Give reasons for non-participation at each stage	16
		(c) Consider use of a flow diagram	16
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	17
		(b) Indicate number of participants with missing data for each variable of interest	16, 17
Outcome data	15*	Report numbers of outcome events or summary measures	17, 18
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	17, 18
		(*b*) Report category boundaries when continuous variables were categorized	8
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n.a.
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	17, 18
Discussion			
Key results	18	Summarise key results with reference to study objectives	18, 19
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	22, 23
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	19, 20, 21
Generalisability	21	Discuss the generalisability (external validity) of the study results	24
Other information			

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	8, 9

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Appendix 2


Site 1
CAD = 12
No CAD = 56
Updated D+F
Initial D+F
Site 2
CAD = 19
No CAD = 36
Site 3
CAD = 24
No CAD = 36
Site 4
CAD = 16
No CAD = 41
Site 5
CAD = 17
No CAD = 43
Site 6
CAD = 9
No CAD = 50
Site 7
CAD = 23
No CAD = 38
Site 8
CAD = 19
No CAD = 36
Site 9
CAD = 15
No CAD = 44
Site 10
CAD = 29
No CAD = 30
True Positive Rate
False Positive Rate



Eur Radiol (2020) Feger S, Ibes P, Napp A et al



Eur Radiol (2020) Feger S, Ibes P, Napp A et al

The 25 clinical sites which recruited patients for the pilot study showed markedly different AUCs. The AUC for the updated D+F ranged between 0.54 (AUC; 95% CI 0.39-0.70) and 0.91 (AUC; 95% CI 0.82-0.99) for the different clinical sites. The AUCs for the initial D+F version ranged between 0.56 (AUC; 95% CI 0.42-0.71) and 0.90 (AUC; 95% CI 0.84-0.98).

The AUCs of the 25 sites were as follows:

Site 1 (AUC initial and updated D+F: 0.67 95% CI 0.51-0.84 and 0.72 95% CI 0.60-0.85 p=0.540)
Site 2 (AUC initial and updated D+F: 0.61 95% CI 0.46-0.76 and 0.62 95% CI 0.48-0.0.77 p=0.629)
Site 3 (AUC initial and updated D+F: 0.90 95% CI 0.83-0.98 and 0.87 95% CI 0.77-0.96 p=0.241)
Site 4 (AUC initial and updated D+F: 0.57 95% CI 0.39-0.75 and 0.60 95% CI 0.42-0.78 p=0.284)
Site 5 (AUC initial and updated D+F: 0.63 95% CI 0.49-0.77 and 0.56 95% CI 0.40-0.71 p=0.011)
Site 6 (AUC initial and updated D+F: 0.62 95% CI 0.44-0.81 and 0.74 95% CI 0.58-0.89 p=0.034)
Site 7 (AUC initial and updated D+F: 0.79 95% CI 0.68-0.91 and 0.80 95% CI 0.68-0.91 p=0.918)
Site 8 (AUC initial and updated D+F: 0.63 95% CI 0.48-0.78 and 0.65 95% CI 0.49-0.81 p=0.780)
Site 9 (AUC initial and updated D+F: 0.71 95% CI 0.54-0.87 and 0.75 95% CI 0.60-0.90 p=0.008)
Site 10 (AUC initial and updated D+F: 0.80 95% CI 0.69-0.91 and 0.84 95% CI 0.74-0.94 p=0.122)
Site 11 (AUC initial and updated D+F: 0.57 95% CI 0.42-0.71 and 0.55 95% CI 0.39-0.70 p=0.791)
Site 12 (AUC initial and updated D+F: 0.66 95% CI 0.52-0.80 and 0.75 95% CI 0.62-0.87 p=0.046)
Site 13 (AUC initial and updated D+F: 0.63 95% CI 0.48-0.77 and 0.65 95% CI 0.50-0.79 p=0.545)
Site 14 (AUC initial and updated D+F: 0.69 95% CI 0.55-0.83 and 0.70 95% CI 0.57-0.84 p=0.632)
Site 15 (AUC initial and updated D+F: 0.73 95% CI 0.58-0.88 and 0.77 95% CI 0.63-0.91 p=0.098)
Site 16 (AUC initial and updated D+F: 0.61 95% CI 0.47-0.76 and 0.64 95% CI 0.49-0.78 p=0.481)
Site 17 (AUC initial and updated D+F: 0.80 95% CI 0.69-0.91 and 0.78 95% CI 0.66-0.90 p=0.484)
Site 18 (AUC initial and updated D+F: 0.63 95% CI 0.48-0.78 and 0.61 95% CI 0.45-0.76 p=0.742)
Site 19 (AUC initial and updated D+F: 0.59 95% CI 0.45-0.74 and 0.64 95% CI 0.50-0.78 p=0.106)
Site 20 (AUC initial and updated D+F: 0.68 95% CI 0.51-0.86 and 0.70 95% CI 0.54-0.87 p=0.532)
Site 21 (AUC initial and updated D+F: 0.74 95% CI 0.61-0.87 and 0.78 95% CI 0.66-0.90 p=0.344)
Site 22 (AUC initial and updated D+F: 0.91 95% CI 0.84-0.98 and 0.91 95% CI 0.83-0.99 p=0.896)
Site 23 (AUC initial and updated D+F: 0.75 95% CI 0.59-0.91 and 0.74 95% CI 0.57-0.91 p=0.563)
Site 24 (AUC initial and updated D+F: 0.64 95% CI 0.51-0.78 and 0.69 95% CI 0.57-0.82 p=0.243)
Site 25 (AUC initial and updated D+F: 0.89 95% CI 0.74-1.00 and 0.0.82 95% CI 0.61-1.00 p=0.428)

Appendix 3

Titel: CT and ICA Equipment Overview and scannerspecific protocols (SSP)

Partner - No.	CT scanner	triphasic/ biphasic protocol	Iterative Reconstruction (IR) avaiable	rows	scanner old	date of scanner change
1	**Toshiba** Aquilion ONE (second genera	triphasic	Yes	320		
2	**Siemens** SOMATOM Definition Flash	biphasic	Yes	256		
3	**Toshiba** Aquilion ONE	biphasic	Yes	320		
4	**Toshiba** Aquilion ONE Vision Edition (s	triphasic	Yes	320		
5	**Siemens** Somatom Definition AS **plus**	biphasic	Yes	128		
6	**Siemens** Somatom Definition Flash	biphasic	No	256		
7	**Philips** Brilliance iCT	triphasic	Yes	256		
8	**Philips** Brilliance	triphasic	Yes	64		
9	**GE** Discovery 750 HD	triphasic	Yes	64		
10	**Siemens** Somatom Definition Flash	biphasic	No	256		
11	**Siemens** Definition DS dual-source	triphasic/ biphasic	No	64		
12	**GE** Optima	biphasic	No	64		
13	**Toshiba** Aquilion ONE (first generation)	biphasic	Yes	320		
14	**Siemens** Somatom Definition Flash	triphasic	Yes	256		
15	**Siemens** Somatom Force				Siemens Somatom Sensation	October 2017
16	**Siemens** Somatom Definition AS **plus**	triphasic	No	128		September 2017
17	**Siemens** Somatom Definition Flash	biphasic	No	256		
18	**Philips**	biphasic	No	128	Siemens Somatom Definition AS plus	
19	**Toshiba** Aquilion ONE	triphasic	Yes	320	GE Discovery 750 HD 64-row scanner	September 2015
20	**Toshiba** Aquilion Premium	triphasic	No	160		
21	**GE** Discovery PET-CT	biphasic	Yes	64		
22	**Siemens** Definition Force (default mach	triphasic	Yes	384 (2 x 192)		
23	**Toshiba** Aquilion CXL	triphasic	Not in CACS	128		
24	**Siemens** Somatom Definiton AS **plus**	biphasic	Yes	128	Definition Dual Source	December 2015
25	**Siemens** Somatom Definition Flash					

Triphasic/biphasic= contrast-injection protocol